FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946965355> ?p ?o ?g. }

• W2946965355 abstract "Background Secukinumab, an inhibitor of IL-17, is a new option for the treatment of Psoriatic Arthritis (PsA) which has showed efficacy in clinical trials. However, real-world data of its use is still scarce. Objectives This study aims to analyze the experience of using secukinumab for PsA in four tertiary hospitals. Methods Multicentric observational, longitudinal, retrospective study conducted in 4 tertiary hospitals of the Madrid region. Patients with clinical diagnosis of PsA and having received at least one dose of secukinumab were included. Medical records were reviewed to collect demographic and clinical data (body mass index, BMI, risk factors cardiovascular disease, cancer, HBV/HCV infection), features of PsA (extra-articular involvement, radiological damage), previous therapies, assessment of the disease and response data at 6 months of secukinumab (joint counts, CRP, DAPSA, reasons for discontinuation, adverse events). Descriptive statistic analysis using mean and standard deviation was performed. Results 177 patients, of which 115 female (65%) were included. Mean age was 53 y.o.(SD 15) and average duration of the disease was 9 years (SD 7). 169 patients (95%) had peripheral disease (34% joint erosions), 84 (47%) had axial disease (68 with radiological damage), 148 (84%) had psoriasis, 61 (34%) showed dactilitis and 111 (63%) had enthesitis. Average BMI was 28.4 (SD 6), with an obesity rate of 37% (52 pt). Observed comorbidities were hypertension (22 pt, 12%), diabetes mellitus (22 pt, 12%), dyslipidemia (58 pt, 33%), active smoking (55 pt, 31%) and others: 20 patients had HBV infection, 5 had HCV infection and 12% had malignancy. Regarding previous treatments, 90% had received cDMARDs, particularly methotrexate (77%) and 119 (67%) had been exposed to at least one bDMARD (32% to one, 25% to two, 20% to three and 21% to four or more). 69% were on 150 mg dose and 31% on 300 mg dose. At baseline, average tender joint count was 7 (SD 8), swollen joint count was 4 (SD 4), CRP 7 mg/l and DAPSA 26. At 6 months of secukinumab therapy, tender joint count had decreased to 5 (SD 8), swollen joint count 2 (SD 3), CRP 5 mg/l and DAPSA 17. Thirty-eight (47%) of the patients with the data available (80) had DAPSA ≤14 (low activity) and 9 DAPSA ≤4 (remission). In naive to biologic patients, DAPSA varied from 27 in the baseline visit to 16 at 6 months, and in the other group of patients with biologic experience, DAPSA varied from 24 to 17 at 6 months (if they had been exposed to 3 or more biologics, DAPSA from 18 to 10 at 6 months). Average drug survival time was 20 months (1-34). 79 patients (44.6%) withdrawn therapy, due to primary ineffectiveness (40), secondary ineffectiveness (26), adverse events (9) and other reasons (3). Adverse events do not differ from those reported in clinical trials. Conclusion Secukinumab in real-world setting had been indicated in a population of PsA with a high percentage of axial involvement (47%), with an important previous exposure to biologics, and with higher comorbidity than that reported in clinical trials. Response data were favorable, 47% of patients achieved remission or low activity by DAPSA, and similar profile of adverse events to the one reported in the clinical trials was observed. References [1] Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. for the FUTURE 1 Study Group* Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med2015;373:1329-39 Disclosure of Interests MARIA MARTIN LOPEZ: None declared, Marta Valero: None declared, Valentina Emperiale: None declared, Carolina Merino Argumanez: None declared, Javier Bachiller-Corral: None declared, Jose Campos Esteban: None declared, Ana Perez Gomez: None declared, Beatriz Joven-Ibanez Speakers bureau: Celgene, Novartis, MSD, Pfizer, AbbVie, and Janssen" @default.
• W2946965355 created "2019-06-07" @default.
• W2946965355 creator A5001325200 @default.
• W2946965355 creator A5006967977 @default.
• W2946965355 creator A5017759854 @default.
• W2946965355 creator A5017875593 @default.
• W2946965355 creator A5055392394 @default.
• W2946965355 creator A5070120923 @default.
• W2946965355 creator A5076849131 @default.
• W2946965355 creator A5091527070 @default.
• W2946965355 date "2019-06-01" @default.
• W2946965355 modified "2023-10-17" @default.
• W2946965355 title "FRI0448 REAL-WORLD EXPERIENCE OF SECUKINUMAB FOR PSORIATIC ARTHRITIS" @default.
• W2946965355 doi "https://doi.org/10.1136/annrheumdis-2019-eular.7452" @default.
• W2946965355 hasPublicationYear "2019" @default.
• W2946965355 type Work @default.
• W2946965355 sameAs 2946965355 @default.
• W2946965355 citedByCount "1" @default.
• W2946965355 countsByYear W29469653552022 @default.
• W2946965355 crossrefType "proceedings-article" @default.
• W2946965355 hasAuthorship W2946965355A5001325200 @default.
• W2946965355 hasAuthorship W2946965355A5006967977 @default.
• W2946965355 hasAuthorship W2946965355A5017759854 @default.
• W2946965355 hasAuthorship W2946965355A5017875593 @default.
• W2946965355 hasAuthorship W2946965355A5055392394 @default.
• W2946965355 hasAuthorship W2946965355A5070120923 @default.
• W2946965355 hasAuthorship W2946965355A5076849131 @default.
• W2946965355 hasAuthorship W2946965355A5091527070 @default.
• W2946965355 hasBestOaLocation W29469653551 @default.
• W2946965355 hasConcept C16005928 @default.
• W2946965355 hasConcept C203014093 @default.
• W2946965355 hasConcept C2776260265 @default.
• W2946965355 hasConcept C2777077863 @default.
• W2946965355 hasConcept C2779786854 @default.
• W2946965355 hasConcept C2780564577 @default.
• W2946965355 hasConcept C71924100 @default.
• W2946965355 hasConceptScore W2946965355C16005928 @default.
• W2946965355 hasConceptScore W2946965355C203014093 @default.
• W2946965355 hasConceptScore W2946965355C2776260265 @default.
• W2946965355 hasConceptScore W2946965355C2777077863 @default.
• W2946965355 hasConceptScore W2946965355C2779786854 @default.
• W2946965355 hasConceptScore W2946965355C2780564577 @default.
• W2946965355 hasConceptScore W2946965355C71924100 @default.
• W2946965355 hasLocation W29469653551 @default.
• W2946965355 hasOpenAccess W2946965355 @default.
• W2946965355 hasPrimaryLocation W29469653551 @default.
• W2946965355 hasRelatedWork W1999169620 @default.
• W2946965355 hasRelatedWork W2167905575 @default.
• W2946965355 hasRelatedWork W2895404113 @default.
• W2946965355 hasRelatedWork W2904527393 @default.
• W2946965355 hasRelatedWork W2920791236 @default.
• W2946965355 hasRelatedWork W2975758879 @default.
• W2946965355 hasRelatedWork W3110645580 @default.
• W2946965355 hasRelatedWork W3194750073 @default.
• W2946965355 hasRelatedWork W3196193197 @default.
• W2946965355 hasRelatedWork W4224235547 @default.
• W2946965355 isParatext "false" @default.
• W2946965355 isRetracted "false" @default.
• W2946965355 magId "2946965355" @default.
• W2946965355 workType "article" @default.